The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > BUSINESS
BUSINESS
- PII Study Confirms Efficacy of Restless Legs Syndrome Treatment: Hisamitsu
October 28, 2014
- OTC Market Grew to 793 Billion Yen in 2013: Yano Research Institute
October 27, 2014
- Japan Arm of Hengrui Medicine Files Campto Generic for Approval
October 27, 2014
- Astellas Revises Package Insert for Xtandi Following Confirmation of Clinical Benefits in PIII Study
October 27, 2014
- Takeda Gains Worldwide Exclusive Rights for Amitiza Excluding Japan and China from Sucampo
October 24, 2014
- Toray Licenses Hemodialysis Pruritus Treatment to Orient EuroPharma in Taiwan
October 24, 2014
- Global Pharma Market to Reach US$1.3 Trillion by FY2018: IMS Official
October 23, 2014
- Taiho Receives Fast Track Designation from US FDA for Lonsurf
October 23, 2014
- US FDA Accepts sNDA for Fycompa: Eisai
October 23, 2014
- Taisho Files NDA for Anti-Inflammatory Analgesic Patch for Osteoarthritis
October 23, 2014
- Obesity Drug Contrave Hits US Pharmacy Shelves: Takeda
October 23, 2014
- MTPC Downwardly Revises Half-Year, Full-Year Sales Forecasts
October 23, 2014
- Takeda Tops Physician Honoraria Payment List in FY2013
October 22, 2014
- Fujifilm to Ratchet Up Avigan Production for Ebola Treatment
October 21, 2014
- Shionogi Cuts Half-Year Net Profit Projection on Back Taxes
October 21, 2014
- Janssen Files Velcade in Japan for Mantle Cell Lymphoma
October 21, 2014
- Ribomic Ready to Out-License Aptamer-Based Drug RBM007
October 21, 2014
- GSK, Sumitomo Dainippon to Wind Up Paxil Copromotion at Year-End
October 21, 2014
- Nippon Boehringer Ingelheim Seeks Japan Approval for Nintedanib
October 21, 2014
- Alexion Submits NDA for Hypophosphatasia Treatment Asfotase Alfa
October 20, 2014
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…